retatrutide phase 2 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Media Centre | EASD
Description
Recent research has raised questions about the impact of GLP-1 receptor agonists on endometrial receptivity and implantation
60 Although modest at the individual level, a 5 mm Hg SBP reduction has been associated with about a 10% lower risk of major cardiovascular events, including 13% reductions in both stroke and heart failure, 8% in ischemic heart disease, and 5% in cardiovascular death, making these effects important at a population level
When can I expect to see results
Once your hunger cues are reset and cravings subside, it becomes easier to maintain healthy habits
